EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fenfluramine in SCN1A-Related Genetic Epilepsy with Febrile Seizures Plus (GEFS+): Toward a Precision Therapeutic Approach

Luisa Kammler, Orazio Palumbo, Mario Benvenuto, Pietro Palumbo, Massimo Carella, Maura Pugliatti, Marco Castori, Giuseppe d’Orsi

Genes · 31.10.2026 · 17 (11) · 1374

DOI: 10.3390/genes17111374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 31.10.2026. Verfasst von Luisa Kammler und 7 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union—Next-Generation EU—PNRR M6/C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SCN1A-related genetic epilepsy with febrile seizures plus (GEFS+) is characterized by marked intrafamilial phenotypic variability, ranging from asymptomatic variant carriers to severe, drug-resistant epilepsy. Methods and Results: We present a two-generation family in which two clinically affected sisters inherited a causative heterozygous SCN1A missense variant (c.3824G>A) from the mother, who likely carries the variant in a mosaic state. The proband, a 23-year-old woman, presented with a long-standing drug-resistant febrile and afebrile epilepsy with onset in early infancy, complicated by mild intellectual disability, impulse control disorder, and behavioral comorbidities, leading to a delayed genetic diagnosis in adulthood. Following insufficient control by multiple antiseizure medications, fenfluramine was introduced at age 21, resulting in complete seizure freedom sustained over two years, alongside measurable neuropsychological improvements in cognition, adaptive functioning, socialization and quality of life.

Conclusions

This case highlights the importance of systematic family history and targeted genetic workup in patients with drug-resistant epilepsy, adds preliminary evidence for fenfluramine beyond Dravet and Lennox–Gastaut syndromes, and illustrates the potential of precise genetic diagnosis to guide treatment in SCN1A-related GEFS+.

Förderung

  • European Union—Next-Generation EU—PNRR M6/C2—Investment 2.1 Enhancement and strengthening of biomedical research in the NHS

Zitieren

APA

Kammler, L., Palumbo, O., Benvenuto, M., Palumbo, P., Carella, M., Pugliatti, M., Castori, M., & d’Orsi, G. (2026). Fenfluramine in SCN1A-Related Genetic Epilepsy with Febrile Seizures Plus (GEFS+): Toward a Precision Therapeutic Approach. Genes, 17(11), 1374. https://doi.org/10.3390/genes17111374

Vancouver

Kammler L, Palumbo O, Benvenuto M, Palumbo P, Carella M, Pugliatti M, et al. Fenfluramine in SCN1A-Related Genetic Epilepsy with Febrile Seizures Plus (GEFS+): Toward a Precision Therapeutic Approach. Genes. 2026;17(11):1374. doi:10.3390/genes17111374

BibTeX
@article{Kammler2026,
  author = {Kammler, Luisa and Palumbo, Orazio and Benvenuto, Mario and Palumbo, Pietro and Carella, Massimo and Pugliatti, Maura and Castori, Marco and d’Orsi, Giuseppe},
  title = {Fenfluramine in SCN1A-Related Genetic Epilepsy with Febrile Seizures Plus (GEFS+): Toward a Precision Therapeutic Approach},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {11},
  pages = {1374},
  doi = {10.3390/genes17111374}
}
Kostenlos starten →